Insight

Patrizia Giannatempo: Phase 1/2 Duravelo-1 study

Patrizia Giannatempo/X

May 28, 2025, 03:50

Patrizia Giannatempo: Phase 1/2 Duravelo-1 study

Patrizia Giannatempo, Medical Oncology Consultant at the National Cancer Institute (INT) in Milan, shared a post on X:

“ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2).
Bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). Encouraging tolerability.”

Title: Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.

Authors: Patrizia Giannatempo, Matthew Galsky, Ignacio Duran, Valentina Boni, Andrea Necchi, Antoine Italiano, Meredith McKean, Loic Verlingue, Rama Balaraman, Leslie DeMars, Kate Josephs, Cong Xu, Oscar Reig Torras

Read the Full Article.

Patrizia Giannatempo

Andrea Necchi Antoine Italiano ASCO25 cancer Cancer research Cong Xu Ignacio Duran Kate Josephs Leslie DeMars Loic Verlingue Matthew Galsky Meredith McKean OncoDaily Oncology Oscar Reig Torras Patrizia Giannatempo Rama Balaraman Valentina Boni

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology